“Transposon’s founding mission was to establish human proof-of-concept that dysregulation of retrotransposable elements in neurodegenerative diseases such as PSP, ALS and Alzheimer’s disease can be addressed with a new class of LINE-1 reverse transcriptase inhibitors,” said Eckard Weber, MD, Transposon’s founder and chief innovation officer. “The results obtained with TPN-101 … show for the first time that neurodegenerative diseases that involve LINE-1 dysregulation are treatable with a specific inhibitor of this important novel target.”
z***** 2月22日 12:22
>>26
この記事の最後のコメント(下記)もそうですが、「PoCの確立」とることを目標にして設立した会社で、承認取得まで目指しているとは言ってないのですよね。
(まあ、Alzheimerに対するPoCはまだ取れてないので、ここ如何では601の価値は大きく違うのですが)
“Transposon’s founding mission was to establish human proof-of-concept that dysregulation of retrotransposable elements in neurodegenerative diseases such as PSP, ALS and Alzheimer’s disease can be addressed with a new class of LINE-1 reverse transcriptase inhibitors,” said Eckard Weber, MD, Transposon’s founder and chief innovation officer. “The results obtained with TPN-101 … show for the first time that neurodegenerative diseases that involve LINE-1 dysregulation are treatable with a specific inhibitor of this important novel target.”
提携して開発スピードを更に上げるのが患者さんのためだと思いますが。